349 related articles for article (PubMed ID: 7557656)
21. Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia.
Sauls DL; Lockhart E; Warren ME; Lenkowski A; Wilhelm SE; Hoffman M
Biochemistry; 2006 Feb; 45(8):2480-7. PubMed ID: 16489740
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of platelet function by contrast media: iopamidol and ioxaglate versus iothalamate. Work in progress.
Rao AK; Rao VM; Willis J; Beckett C; Steiner RM
Radiology; 1985 Aug; 156(2):311-3. PubMed ID: 4011893
[TBL] [Abstract][Full Text] [Related]
23. Differential effects of the iodinated contrast agents Ioxaglate, Iohexol and Iodixanol on thrombus formation and fibrinolysis.
Jones CI; Goodall AH
Thromb Res; 2003; 112(1-2):65-71. PubMed ID: 15013276
[TBL] [Abstract][Full Text] [Related]
24. Fibrin clots obtained from plasma containing heparin show a higher sensitivity to t-PA-induced lysis.
Nenci GG; Parise P; Morini M; Rossini A; Agnelli G
Blood Coagul Fibrinolysis; 1992 Jun; 3(3):279-85. PubMed ID: 1643205
[TBL] [Abstract][Full Text] [Related]
25. Altered plasma fibrin clot properties in essential thrombocythemia.
Małecki R; Gacka M; Kuliszkiewicz-Janus M; Jakobsche-Policht U; Kwiatkowski J; Adamiec R; Undas A
Platelets; 2016; 27(2):110-6. PubMed ID: 25989112
[TBL] [Abstract][Full Text] [Related]
26. Assessment of fibrinolytic activity by measuring the lysis time of a tissue-factor-induced clot: a feasibility evaluation.
Cellai AP; Lami D; Magi A; Liotta AA; Rogolino A; Antonucci E; Bandinelli B; Abbate R; Prisco D
Clin Appl Thromb Hemost; 2010 Jun; 16(3):337-44. PubMed ID: 19117964
[TBL] [Abstract][Full Text] [Related]
27. Factor XI enhances fibrin generation and inhibits fibrinolysis in a coagulation model initiated by surface-coated tissue factor.
von dem Borne PA; Cox LM; Bouma BN
Blood Coagul Fibrinolysis; 2006 Jun; 17(4):251-7. PubMed ID: 16651866
[TBL] [Abstract][Full Text] [Related]
28. Peroxynitrite may affect fibrinolysis via the reduction of platelet-related fibrinolysis resistance and alteration of clot structure.
Misztal T; Rusak T; Brańska-Januszewska J; Ostrowska H; Tomasiak M
Free Radic Biol Med; 2015 Dec; 89():533-47. PubMed ID: 26454084
[TBL] [Abstract][Full Text] [Related]
29. [Activation of blood coagulation and fibrinolysis after angiocardiography with ionic and non-ionic contrast media].
Winkler UH; Park JW; Weber S; Kothe A; Schnitker J; Behrends-Steins B; Albring M
Rofo; 1997 Jun; 166(6):539-43. PubMed ID: 9273008
[TBL] [Abstract][Full Text] [Related]
30. Effects of low molecular weight heparins on fibrin polymerization and clot sensitivity to t-PA-induced lysis.
Parise P; Morini M; Agnelli G; Ascani A; Nenci GG
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):721-7. PubMed ID: 8292721
[TBL] [Abstract][Full Text] [Related]
31. Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets.
Torr-Brown SR; Sobel BE
Thromb Res; 1993 Dec; 72(5):413-21. PubMed ID: 8303684
[TBL] [Abstract][Full Text] [Related]
32. Effects of ionic and nonionic contrast media on endothelium and on arterial thrombus formation.
Barstad RM; Buchmann MS; Hamers MJ; Orning L; Orvim U; Stormorken H; Sakariassen KS
Acta Radiol; 1996 Nov; 37(6):954-61. PubMed ID: 8995473
[TBL] [Abstract][Full Text] [Related]
33. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
Guimarães AH; Rijken DC
Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
[TBL] [Abstract][Full Text] [Related]
34. Qualitative description of factors involved in the retraction and lysis of dilute whole blood clots and in the aggregation and retraction of platelets.
Taylor FB; Müller-Eberhard HJ
J Clin Invest; 1970 Nov; 49(11):2068-85. PubMed ID: 4248913
[TBL] [Abstract][Full Text] [Related]
35. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots.
Semeraro F; Piro D; Rossiello MR; Ammollo T; Colucci M
Thromb Haemost; 2007 Dec; 98(6):1208-14. PubMed ID: 18064315
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of concomitant thrombin-mediated fibrin formation enhances clot lysis in whole blood.
Haskel EJ; Eisenberg PR; Abendschein DR
Blood Coagul Fibrinolysis; 1993 Feb; 4(1):7-13. PubMed ID: 8457655
[TBL] [Abstract][Full Text] [Related]
37. Iohexol, platelet activation and thrombosis. II. Iohexol-induced platelet secretion does not affect collagen-induced or tissue-factor-induced thrombus formation in blood that is anticoagulated with heparin and aspirin.
Sakariassen KS; Buchmann M; Hamers MJ; Stormorken H
Acta Radiol; 1998 Jul; 39(4):355-61. PubMed ID: 9685818
[TBL] [Abstract][Full Text] [Related]
38. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis.
Konieczynska M; Fil K; Bazanek M; Undas A
Thromb Haemost; 2014 Apr; 111(4):685-93. PubMed ID: 24306139
[TBL] [Abstract][Full Text] [Related]
39. Effect of fibrin structure on plasmin-mediated dissolution of plasma clots.
Carr ME; Alving BM
Blood Coagul Fibrinolysis; 1995 Sep; 6(6):567-73. PubMed ID: 7578900
[TBL] [Abstract][Full Text] [Related]
40. Microfluidic Modeling of Thrombolysis.
Loyau S; Ho-Tin-Noé B; Bourrienne MC; Boulaftali Y; Jandrot-Perrus M
Arterioscler Thromb Vasc Biol; 2018 Nov; 38(11):2626-2637. PubMed ID: 30354249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
